

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims**

1. (Previously presented) An isolated tolerogenic dendritic cell comprising an oligodeoxyribonucleotide having one or more NF-κB binding sites, wherein the oligodeoxyribonucleotide inhibits NF-κB transcriptional activity, and wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.
2. (Previously presented) The isolated tolerogenic dendritic cell of claim 1 wherein the oligodeoxyribonucleotide sequence has two NF-κB binding sites.
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Previously presented) A method of producing an isolated tolerogenic dendritic cell comprising (a) propagating an immature isolated dendritic cell from a mammalian donor, (b) incubating the immature isolated dendritic cell with an oligodeoxyribonucleotide having at least one NF-κB binding site under conditions wherein the immature isolated dendritic cell internalizes the oligodeoxyribonucleotide, wherein the oligodeoxyribonucleotide inhibits NF-κB transcriptional activity and (c) culturing the isolated dendritic cell of (b) to produce the isolated tolerogenic dendritic cell, and wherein the oligodeoxyribonucleotide has the sequence set forth in NY02:511370.1

SEQ ID NO:1.

8. (Cancelled)
9. (Previously presented) The method of claim 7 further comprising incubating the isolated tolerogenic dendritic cell in the presence of one or more cytokine(s).
10. (Original) The method of claim 9 wherein the cytokine is GM-CSF.
11. (Previously presented) The method of claim 9 further comprising incubating the isolated tolerogenic dendritic cell in the presence of TGF- $\beta$ .
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)

26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Previously presented) A kit for enhancing tolerogenicity in a mammalian host comprising tolerogenic dendritic cells which comprise an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site, wherein the oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity, and wherein the oligodeoxyribonucleotide has a sequence set forth in SEQ ID NO:1.
  31. (Cancelled)
  32. (Cancelled)
  33. (Cancelled)
  34. (Cancelled)
  - 35-67. (Cancelled)